Gilead agrees 127-country remdesivir licence with generic makers
Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
US judge dismisses attorney’s ‘opportunistic’ whistleblower suit
A Californian judge has thrown out an attorney’s whistleblower lawsuit alleging Bausch Health Companies fraudulently obtained a patent for its ulcerative colitis drug Apriso.
US government urges SCOTUS to deny retroactive IPR suit
The US Supreme Court should not take up a petition asking whether it’s a violation of the Fifth Amendment for patents issued before the enactment of the American Invents Act to be subjected to inter partes reviews, according to the US government.
Merck expands CRISPR patent portfolio
Merck has added two US patents to its CRISPR-Cas9 patent portfolio, and is already seeking licensing and product development partners, the German company announced yesterday, May 11.
3M price-gouging case ‘crumbles like cookie’, says accused company
A trademark infringement complaint filed by 3M is “short on ultimate facts and long on inflammatory, derogatory, and conclusory assertions”, according to the company accused of price-gouging in the suit.
NASA lab offers respirator designs for free
A California spacecraft laboratory has made its respirator designs available for free and signed up to the IP sharing scheme, Open COVID Pledge.
Fed Circuit affirms generic maker’s win over Eagle
The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
HGF promotes two to partner
IP firm HGF has appointed two patent attorneys to partner, increasing the partner group to 63 partners.
USPTO temporarily allows online plant patent filings
The US Patent and Trademark Office will allow plant patent applications to be filed online due to the COVID-19 pandemic, it has announced.
Bausch Health resolves IBS patent litigation
Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
